The second edition of the Florence POST-CROI Conference was conceived with the objective to offer a platform of knowledge and discussion to those who normally have not the opportunity to participate, in person, to the important American event which annually “takes stock” on the scientific cutting-edge themes regarding Retroviruses and related opportunistic infections.
The Convention stands as a valid and reliable opportunity to explore duly, with the mediation of the authoritative contributions of experts along with the qualified discussions of the audience, the most important news and progressions of research emerged from the clinical sections selected by the scientific committee of CROI.
We intended thus to respond to all wishes and solicitations received by the organizers from the participants who attended the first event, held in March 2015. They widely expressed in fact their appreciation on the high scientific quality of the critical explorations proposed in real time of the news and controversies arisen from the hot topics of CROI 2015.
The interactive review of the clinical sessions, discussed in a videoconference with the Johns Hopkins University’s experts, will interpose with Round Tables and Lectures focusing on current aspects of epidemiology and clinical pharmacology.
In this edition, the Foundation for Infectious Diseases and International Health (MISI), promoter of Florence POST CROI 2016, aims to extend its interest and scope, encouraging the participation of young clinicians and postgraduates that are directly involved in clinical and research activities.
The presence in the faculty of many experts from Europe and from Johns Hopkins, flanked by the presence of selected researchers and members of different Italian and International Institutions, allows to analyze with realistic awareness the credibility of what is essentially the elective goal of our initiative: the prospective elimination of endemoepidemic of HIV, co-infections and related pathologies through education, prevention and the broader and differentiated commitment on the most current antiviral therapies..